Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20115685 | 0.90 | F2 (0.32) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL14191224 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL8037005 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL2133849 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL8320089 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL3793642 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL13646429 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL13630595 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL3793643 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 | |
| SCHEMBL3669860 | 0.86 | ADRB3 (0.40) | F2F10PRSS1GAAADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7566719-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-07-28 | — | — | US | disclosed |